bumped 激酶抑制剂 1369 在猪隐孢子虫急性腹泻模型中的治疗效果。
Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium hominis.
机构信息
Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA.
Department of Medicine, Division of Allergy and Infectious Disease, Center for Emerging and Reemerging Infectious Disease (CERID), University of Washington, Seattle, Washington, USA.
出版信息
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00147-18. Print 2018 Jul.
Abstract
Recent reports highlighting the global significance of cryptosporidiosis among children have renewed efforts to develop control measures. We evaluated the efficacy of bumped kinase inhibitor (BKI) 1369 in the gnotobiotic piglet model of acute diarrhea caused by , the species responsible for most human cases. Five-day treatment with BKI 1369 reduced signs of disease early during treatment compared to those of untreated animals. Piglets treated with BKI 1369 exhibited significant reductions of oocyst excretion, mucosal colonization by , and mucosal lesions, which resulted in considerable symptomatic improvement. BKI 1369 reduced the parasite burden and disease severity in the gnotobiotic pig model. Together these data suggest that a BKI-mediated therapeutic may be an effective treatment against cryptosporidiosis.
摘要
最近的报告强调了隐孢子虫病在儿童中的全球意义，这促使人们再次努力制定控制措施。我们评估了 bumped kinase 抑制剂（BKI）1369 在由导致大多数人类病例的物种引起的急性腹泻的无菌仔猪模型中的疗效。与未治疗的动物相比，BKI 1369 的 5 天治疗在治疗早期减轻了疾病症状。用 BKI 1369 治疗的仔猪的卵囊排泄、 和粘膜定植以及粘膜损伤显著减少，这导致症状有了相当大的改善。BKI 1369 减少了无菌猪模型中的寄生虫负担和疾病严重程度。这些数据表明，BKI 介导的治疗可能是一种有效的隐孢子虫病治疗方法。
相似文献
1
Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium hominis.
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00147-18. Print 2018 Jul.
2
Piperazine-Derivative MMV665917: An Effective Drug in the Diarrheic Piglet Model of Cryptosporidium hominis.
J Infect Dis. 2019 Jun 19;220(2):285-293. doi: 10.1093/infdis/jiz105.
3
The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominis.
PLoS One. 2017 Oct 3;12(10):e0185906. doi: 10.1371/journal.pone.0185906. eCollection 2017.
4
P-Glycoprotein-Mediated Efflux Reduces the In Vivo Efficacy of a Therapeutic Targeting the Gastrointestinal Parasite Cryptosporidium.
J Infect Dis. 2019 Aug 30;220(7):1188-1198. doi: 10.1093/infdis/jiz269.
5
Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis.
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0142522. doi: 10.1128/aac.01425-22. Epub 2023 Mar 15.
6
Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis.
J Infect Dis. 2016 Dec 15;214(12):1856-1864. doi: 10.1093/infdis/jiw488. Epub 2016 Oct 17.
7
The piglet acute diarrhea model for evaluating efficacy of treatment and control of cryptosporidiosis.
Hum Vaccin Immunother. 2019;15(6):1445-1452. doi: 10.1080/21645515.2018.1498436. Epub 2018 Aug 27.
8
A Novel Calcium-Dependent Kinase Inhibitor, Bumped Kinase Inhibitor 1517, Cures Cryptosporidiosis in Immunosuppressed Mice.
J Infect Dis. 2016 Dec 15;214(12):1850-1855. doi: 10.1093/infdis/jiw481. Epub 2016 Oct 12.
9
A novel CDPK1 inhibitor--a potential treatment for cryptosporidiosis in calves?
Parasitol Res. 2015 Jan;114(1):335-6. doi: 10.1007/s00436-014-4228-7. Epub 2014 Nov 15.
10
Pyrrolopyrimidine Bumped Kinase Inhibitors for the Treatment of Cryptosporidiosis.
ACS Infect Dis. 2021 May 14;7(5):1200-1207. doi: 10.1021/acsinfecdis.0c00803. Epub 2021 Feb 10.
引用本文的文献
1
Microbiome analysis reveals gut bacterial alterations in adult Tibetan pigs with diarrhea.
Front Microbiol. 2025 Jun 30;16:1524727. doi: 10.3389/fmicb.2025.1524727. eCollection 2025.
2
Microphysiological gut-on-chip enables extended development of .
Front Cell Infect Microbiol. 2025 Apr 24;15:1564806. doi: 10.3389/fcimb.2025.1564806. eCollection 2025.
3
Molecular pathogenesis of Cryptosporidium and advancements in therapeutic interventions.
Parasite. 2025;32:7. doi: 10.1051/parasite/2025001. Epub 2025 Feb 4.
4
Understanding the species and their challenges to animal health and livestock species for informed development of new, specific treatment strategies.
Front Parasitol. 2024 Aug 6;3:1448076. doi: 10.3389/fpara.2024.1448076. eCollection 2024.
5
Pyridopyrimidinones as a new chemotype of calcium dependent protein kinase 1 (CDPK1) inhibitors for Cryptosporidium.
Mol Biochem Parasitol. 2024 Dec;260:111637. doi: 10.1016/j.molbiopara.2024.111637. Epub 2024 Jun 18.
6
Anti-Cryptosporidial Drug-Discovery Challenges and Existing Therapeutic Avenues: A "One-Health" Concern.
Life (Basel). 2024 Jan 3;14(1):80. doi: 10.3390/life14010080.
7
Scalable cryopreservation of infectious Cryptosporidium hominis oocysts by vitrification.
PLoS Pathog. 2023 Jun 8;19(6):e1011425. doi: 10.1371/journal.ppat.1011425. eCollection 2023 Jun.
8
Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis.
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0142522. doi: 10.1128/aac.01425-22. Epub 2023 Mar 15.
9
Past, current, and potential treatments for cryptosporidiosis in humans and farm animals: A comprehensive review.
Front Cell Infect Microbiol. 2023 Jan 24;13:1115522. doi: 10.3389/fcimb.2023.1115522. eCollection 2023.
10
Diagnosis and control of cryptosporidiosis in farm animals.
J Parasit Dis. 2022 Dec;46(4):1133-1146. doi: 10.1007/s12639-022-01513-2. Epub 2022 Jul 4.
本文引用的文献
1
The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominis.
PLoS One. 2017 Oct 3;12(10):e0185906. doi: 10.1371/journal.pone.0185906. eCollection 2017.
2
Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis.
Int J Parasitol. 2017 Oct;47(12):753-763. doi: 10.1016/j.ijpara.2017.08.006. Epub 2017 Sep 9.
3
Extended-spectrum antiprotozoal bumped kinase inhibitors: A review.
Exp Parasitol. 2017 Sep;180:71-83. doi: 10.1016/j.exppara.2017.01.001. Epub 2017 Jan 5.
4
Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis.
J Infect Dis. 2016 Dec 15;214(12):1856-1864. doi: 10.1093/infdis/jiw488. Epub 2016 Oct 17.
5
Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.
J Med Chem. 2016 Jul 14;59(13):6531-46. doi: 10.1021/acs.jmedchem.6b00760. Epub 2016 Jul 1.
6
The Burden of Cryptosporidium Diarrheal Disease among Children < 24 Months of Age in Moderate/High Mortality Regions of Sub-Saharan Africa and South Asia, Utilizing Data from the Global Enteric Multicenter Study (GEMS).
PLoS Negl Trop Dis. 2016 May 24;10(5):e0004729. doi: 10.1371/journal.pntd.0004729. eCollection 2016 May.
7
Continuous culture of Cryptosporidium parvum using hollow fiber technology.
Int J Parasitol. 2016 Jan;46(1):21-9. doi: 10.1016/j.ijpara.2015.07.006. Epub 2015 Sep 2.
8
Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED).
Lancet Glob Health. 2015 Sep;3(9):e564-75. doi: 10.1016/S2214-109X(15)00151-5. Epub 2015 Jul 19.
9
A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.
Lancet Infect Dis. 2015 Jan;15(1):85-94. doi: 10.1016/S1473-3099(14)70772-8. Epub 2014 Sep 29.
10
Potent and selective inhibitors of CDPK1 from and based on a 5-aminopyrazole-4-carboxamide scaffold.
ACS Med Chem Lett. 2014 Jan 9;5(1):40-44. doi: 10.1021/ml400315s.
Zotero 插件